Tom Stone, MD, on the Midterms | Ehsan Rahimy, MD, on the PRIMA Implant
Hosts: John Kitchens, MD, Scott Krzywonos
Topics Covered
Business of Retina After the Midterms (Thomas Stone, MD)
Scott floats a thesis that 2026 echoes 2006, and that the healthcare reform of 2008 could occur again in 2028 if a Democrat takes the White House. John and Tom expect little legislative change before 2029 because of the presidential veto, but see the results giving Democrats a platform on healthcare.
Tom’s watch list: continued pressure on surgical reimbursement. Expansion of Inflation Reduction Act drug negotiation, with 20 more drugs selected in 2027 and talk of 50. Proposals to shorten the biologic timeline from 11 years to 5. Medicare expansion options, including a public option and a lower eligibility age.
GLOBE Project: Tom says it is not high on his radar. John expects the impact to fall on manufacturers and distributors more than on practice drug reimbursement.
2027 practice economics: biosimilars have created a market practices must respond to. Tom points to Lucentis, where ASP erosion left practices underwater.
Patient assistance: after two years of uncertainty in Medicare Advantage copay foundation funding, a fund covering several hundred of Tom’s patients sunset in October. Practices need to be ready to enroll patients the moment funds open.
Meetings: Tom previews the Cencora Vision Exchange in Orlando and the March 2027 Business of Retina meeting, which will feature a keynote speaker from Microsoft covering AI, as well as sessions on staffing and recruitment.
Vitreoretinal View: PRIMA Implant (Ehsan Rahimy, MD)
The device: a 2 x 2 mm, 30 µm photovoltaic chip with 378 pixels, placed subretinally with no battery or cables. Glasses with a camera and pocket processor project near infrared light onto the chip, which stimulates bipolar cells. Patients combine form vision with native peripheral vision.
The surgery: pars plana vitrectomy, subretinal bleb, roughly 3 mm retinotomy, a pick to separate adherent retina at the GA border, and perfluorocarbon to stabilize the chip on insertion. Tamponade is required (70% gas, 30% oil in PRIMAvera). No retinotomy laser.
Rehabilitation: more than 60 hours of structured training. Dr. Rahimy expects US centers of excellence.
Outcomes: ~25 ETDRS letters gained at 12 months and about 30 at 36 months. 84% of compliant participants reported reading letters and words, and 52% used the device for complex tasks such as playing cards. Entry acuity was no better than 20/320 in the study eye and 20/200 in the fellow eye.
Safety: 38 patients, 17 sites, five countries. 27 completed 36 months. Seven died of all-cause mortality, none attributed to the device or procedure. 29 serious adverse events, 83% within 6 months. Natural vision was preserved. Placement in maculas 50 µm or thinner is best avoided.
Compared to Argus II: Argus is epiretinal and RF powered, with about 60 electrodes and extraocular cables. PRIMA is subretinal, uses 378 pixels at 100 µm pitch, and did not migrate beyond GA borders.
FDA: two Humanitarian Use Device designations, for advanced GA and Stargardt disease. Dr. Rahimy says Science Corporation has filed for a Humanitarian Device Exemption, with a decision possible by year end or early 2027. Candidates need pure GA with intact inner retina, so concurrent glaucoma would exclude a patient.
Key Takeaways
The hosts see little chance of healthcare legislation before 2029, but drug pricing and reimbursement debates could reach retina sooner.
The market, more than politics, is driving 2027 practice economics: biosimilars, ASP erosion, and shifting patient assistance funds.
PRIMAvera showed functional central vision gains in end-stage GA with a manageable safety profile, and a US decision could come within months.
Candidates are narrow: advanced GA, intact inner retina, and capacity for extensive rehabilitation.
Sponsors
This episode of RetinUp is supported by Genentech, Astellas, and Alcon.
Credits
Production & Marketing: Laura Brown | Business Operations: Liz Hogan
🎧 Listen at RetinUp.com | Apple Podcasts | Spotify | YouTube